• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Melatonin for Insomnia in Patients With Autism

Melatonin for Insomnia in Patients With Autism

June 11, 2019
Jess Levy, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jess Levy, MD. Dr. Levy has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Maras A et al, J Child Adolesc Psychopharmacol 2018;28(10):699–710

Treating sleep problems in youth with autism spectrum disorder (ASD) is tricky at best. One promising treatment is pediatric prolonged-release melatonin ­(PedPRM) sold under the name Slenyto. In 2017, a randomized controlled trial (funded by the manufacturer) assigned 119 children with ASD and insomnia to either PedPRM (n = 58) or placebo (n = 61). PedPRM outperformed placebo: 68.9% of patients taking the medication had improved sleep outcomes vs only 39.3% of those assigned to placebo (p = .001).

Now a new article has been published to determine whether PedPRM maintains its effectiveness over the long term. A total of 95 patients entered this open-label phase, and 84% (n = 80) completed the phase. The average age of the patients was 9 years, and 75% were male. Youths previously randomized to placebo were switched to PedPRM and titrated to a maximum dose of 10 mg/day.

After 37 weeks, children originally randomized to and maintained on PedPRM showed sustained improvements: shorter sleep latency, greater length of sleep, fewer awakenings, and better sleep quality. In addition, those who previously received placebo showed improvement in sleep length and onset after switching to PedPRM. Caregivers’ quality of life improved as well, with 49% of caregivers experiencing an improvement on the quality-of-life scale used in the study.

The most common side effect of PedPRM was daytime fatigue, which occurred in 18% of the patients. There were no serious adverse events attributed to the medication, including aggression.

CCPR’s Take
This industry-funded study reports compelling results, which begs us to presume bias despite what appears to be sound methodology. It would be helpful to see a head-to-head study vs over-the-counter melatonin, which is cheaper albeit with less reliable pill-to-pill variability.

Still, PedPRM may be a viable treatment option for children with autism and insomnia who have failed a comprehensive sleep hygiene approach including attention to sensory issues, daily exercise, and psychotherapy, all of which might be effective in this population.
Child Psychiatry
KEYWORDS autism child_psychiatry research-update sleep_disorders
Jess Levy, MD.

Using an Interpreter in Psychiatric Practice

More from this author
www.thecarlatreport.com
Issue Date: June 11, 2019
SUBSCRIBE NOW
Table Of Contents
Note From the Editor-in-Chief
Medications for Depression
Practical Approaches to Vetting Clinical Research
FDA Approves Adhansia XR
First Non-Drug Treatment Approved by FDA for Treating Children With ADHD
Prescribing Patterns for Children With Anxiety Disorders
Melatonin for Insomnia in Patients With Autism
Steroid-Induced Psychosis in the ­Pediatric Population
Risk of Psychosis With Stimulants in ADHD Patients
Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents
CME Post-Test - Depression in Children and Adolescents, CCPR, Summer 2019
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    (PRE-ORDER) Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto52138604.jpg
    Child Psychiatry

    Readily Available and Easily Abused Over-the-Counter Medications

    Reviewing four commonly abused substances that are legally available for purchase: Dextromethorphan, antihistamines, pseudoephedrine, and Kratom.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.